NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Lotus Pharmaceuticals back to previous page show list

Lotus Pharmaceuticals

address: Lotus Pharmaceuticals, Inc.
c/o Liang Fang Pharmaceuticals Co., Ltd.
16 Cheng Zhuang Road, Feng Tai District
Beijing 100071 People's Republic of China
contact: Telephone: (8610) 6389 9868
Facsimile: (8610) 6389 9867
key person: Dr. Liu Zhong Yi, Chairman, CEO & President

Adam Wasserman, Chief Financial Officer

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 268

active in China: YES

SFDA approved: YES
SFDA approved date: 12/01/2001

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: NO
Ingredients: NO
Western Generics: YES
TCM: YES

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: YES
API: YES
Licensed Drugs: YES

test:
R&D: NO
 
Lotus is an emerging Chinese leader in offering medicines to ensure well-being, cure disease and improve quality of life. Their goal is to discover, develop and successfully market innovative products to help people globally, to help patients manage afflictions and to enhance the quality of life. 
Lotus has a unique positioning amongst major pharmaceutical companies in China, as it resides in a small class of leadership in both patented and generic pharmaceuticals.They are strengthening  medicine-based portfolio, investing in strategic growth platforms:
• Innovation-driven prescription medicines
• Cost-effective and high-quality generic medicines
• Retail Sales of leading self-medication (OTC) brands
• Human vaccines that address public health and therapeutic needs
Lotus continues to discover, develop and successfully market innovative products to help people globally, to help patients manage afflictions and to enhance the quality of life. Lotus has a unique positioning amongst major pharmaceutical companies in China, as it resides in a small class of leadership in both patented and generic pharmaceuticals.
Lotus leads the regional industry with 14 new product approvals in the China since 2000, with key approvals in 2005. Lotus will make VALSARTAN the number one prescribed brand in its class of high blood pressure medications in China. Lotus owns and operates 10 retail outlets throughout metropolitan Beijing.
 
Management
Under the authority of Dr. Liu Zhongyi, CEO of Lotus Pharmaceuticals, the Executive Committee coordinates the implementation of strategies for the Group and the allocation of the required resources. Management is committed to serving the interests of the entire enterprise and achieving a sustained increase in corporate value. Dr. Liu coordinates the principles of corporate policy.
The most important tasks of the Management are defining corporate strategy, setting the budget and allocating corporate resources. The Board of Directors also ensures that the shareholders receive regular, timely and comprehensive information on all matters relating to Lotus’s planning, business development and risk management.
 
Dr. Liu Zhong Yi
Dr. Liu Zhong Yi, Chairman, CEO & President, is the founder of Lotus Pharmaceuticals, Inc. in the United States and its Chinese antecedent, Liang Fang Pharmaceuticals Co., Ltd. in Beijing. He earned his Master’s Degree in Beijing hospitals, after doing his undergraduate studies in his homeland of Inner Mongolia. Dr. Liu holds the title of Deputy Chief Physician, as a professional apothecary, in operating Lotus (Liang Fang) as one of China’s most innovative and fastest growing pharmaceutical companies.
 
As a researcher and medical student, Dr. Liu excelled in the development of many new drugs in wide use in China today. While working for the Chinese Government in 1992, he established the Research Center of Space Flight Biological Engineering Technology, and continued his renowned research related to incretion diseases. Four years later, entering the private sector and invigorated by burgeoning capitalism in China, Dr. Liu started his first pharmaceutical company in Beijing.

The year 1999 marked a landmark for Dr. Liu and his company by the introduction of
VALSARTAN, China’s most effective and popular drug for the treatment of hypertension. During this same period, he commenced his hugely successful retail drug stores that now number 10 throughout Greater Beijing.

In early 2006, Dr. Liu aligned his operations with Genesis Equity Partners, LLC, the U.S.-based capital investment firm. Lotus Pharmaceuticals, Inc. (OTCBB: LOTS) became a NASDAQ Bulletin Board Company when it officially commenced trading on month, day, 2006.
 
Adam Wasserman
Adam Wasserman, Chief Financial Officer, is a highly effective financial executive with demonstrated success in increasing the profitability and value of companies. Throughout his career he has been an integral member of executive management responsible for financial and accounting. He has a strong background in financial reporting, budgeting and planning, mergers and acquisitions, auditing, accounting, automated systems, banking relations and internal controls. Mr. Wasserman was an audit manager at American Express Tax & Business in Fort Lauderdale , Florida .
 
During his tenure as manager, Mr. Wasserman successfully acted as an outsourced CFO and advisor to a diversified clientele in the wholesale, technology, distribution, medical, retail, and service industries in both the private and public sector. His responsibilities included supervising, training and evaluating senior staff members, work paper review, auditing, maintaining positive client relations, preparation of tax returns and preparation of financial statements and the related footnotes. Mr. Wasserman has experience with SEC filings such as initial public offerings, 10-Ks and 10-Qs. Prior to this, Mr. Wasserman was with Deloitte & Touche, LLP in New York City . Significant assignments included audits of public (SEC reporting) and private companies, tax preparation and planning, management consulting, systems design, staff instruction, and recruiting. Mr. Wasserman holds a Bachelor of Administration from the State University at Albany in Albany , New York . He is a CPA and a member of The American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants. On several occasions, Mr. Wasserman has traveled to China to assist companies in transforming to GAPP and SEC reporting enterprises.
 
Facilities and Facts
Lotus Pharmaceuticals, Ltd. has its registered address at No. 18, Construction Road on the Liang Xiang Triumph Street in Fangshan District, Beijing and is No.16 on the Chengzhuang Road in Fengtai District, Beijing. It has a registered capital of 40 million yuan (about $5 million) and deals mainly in the wholesale marketing of patented Chinese medicine, Western preparations, bio-and chemo-medicine, bio-drugs, medical treatment appliances, and packaging food.
The sole domestic franchisee of the Beijing is En Ze Jia Shi Pharmaceuticals Ltd. At present, there are altogether over 200 personnel in the Company, amongst which, over 150 have the degree of junior college or above, 10 are apothecaries with work license, 6 are apothecaries and director apothecaries.
The Corporation has attached organs of offices, financials department, quality management department, supplying department, storage and delivery department etc. Its main facilities includes an office building of 1,500 square meters, normal temperature rooms of 810 square meters, low temperature rooms of 60 square meters, refrigerator of 16.8 cubic meters, drug inspection rooms of 120 square meters and conserving rooms of 60 square meters, as well as other equipment and regulations to support these. Especially, the Corporation has drawn a detailed set of regulations and principles of drug dealings and has carried out them strictly in practices.
With 18 offices amongst the whole country to provide high-quality products and rapid, effective post-sale services to its clients, Beijing En Ze Jia Shi Pharmacy Ltd. is a medicine-making company with a registered capital of 19 million yuan about $2.25 million) and is built upon the collective investment of Mr. Liu Zhongyi, the board chairman of the Liang Fang Pharmaceuticals Group Corporation and the Jia Shi Tang Pharmaceutical Ltd., which is under the command of the Central Committee of the Communist Youth Group. It is also located on the Double-Bridge Road in Chaoyang District, with an area of 7,000 square meters and a floor space of 5,000 square meters.
This Center is located in the middle of the Double-Bridge Road in Chaoyang District, Beijing and covers a floor space of 600 square meters. It possesses an integral set of equipment of liquid and gas chromatography, action and mass spectrum, and different kinds of facilities for purification and distillation, all of which make it quite capable of the production of biosynthesis medicine, patented Chinese medicine, chemosynthesis, and bacteriophage as well as the research and production of other new medicines. Over 20 people work in this Center, more than 90% of whom hold a bachelor’s degree or above in high-tech medication development.
At present, the total investment of this Company has amounted to 80 million yuan (about $10 million). As one of the first enterprises to be authenticated by the National GMP, the Company boasts of the most advanced automatic zed pharmacy product lines of the country and the GMP authenticated certificate number are C0849, C0850, D1645, and G3452. Medicines produced by the Company include material medicine, troches, capsules, granule medicaments; freeze-dried powder for injections, injections of small capacities and eye drops. Presently, the Company has developed five new medicines; there currently in production and sales, also there are scores of other new medicines still under report for production. It is estimated that all these medicines will be put into production and sales by the end of the year.
 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.